Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study

The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2025-03-28
DOI
https://doi.org/10.3390/cancers17071137
Citations
3
Primary Topic
Cutaneous lymphoproliferative disorders research
Type
article
Field-Weighted Citation Impact
6.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study

Antonio M. Gutierrez, Carmen Martı́nez, Javier López‐Jiménez, Antonia Rodríguez-Izquierdo et al.
3 citations
Cancers
Cutaneous lymphoproliferative disorders research
6.01
article

Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study

Antonio M. Gutierrez, Carmen Martı́nez, Javier López‐Jiménez, Antonia Rodríguez-Izquierdo, M Grande, Eva Domingo‐Doménech, Pablo Luis Ortiz-Romero, María Stefanía Infante, Ramón García‐Sánz, Pilar Giraldo, Blanca Sánchez‐González, Anna Sureda, David Aguiar‐Bujanda, Lourdes Baeza-Montañez, F. Capote
article en
3 citations

Abstract

The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies.

CancersVol. 17(7)
Universidad de Alcalá (ES), Instituto Cajal (ES), Hospital General Universitario Gregorio Marañón (ES), Research Institute Hospital 12 de Octubre (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Laboratorios Farmaceúticos Rovi (Spain) (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Hospital Quirónsalud Barcelona (ES), Hospital Clínic de Barcelona (ES), Health Research Institute of the Balearic Islands (ES), Hospital Del Mar (ES), Duran i Reynals Hospital (ES), Hospital Universitario Puerta del Mar (ES), Hospital Universitario Son Espases (ES), Centro de Investigación Biomédica en Red de Cáncer (ES), Hospital Universitario Infanta Leonor (ES)
Openalex Percentile: Top 5%
Cutaneous lymphoproliferative disorders research
6.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.